糖尿病黄斑水肿(DME):剖析发病机制、预后、诊断方法以及当前和未来的治疗见解。

IF 1.9 Q2 OPHTHALMOLOGY
Ahmed Sermed Al Sakini, Abdulrahman Khaldoon Hamid, Zainab A Alkhuzaie, Sandra Thair Al-Aish, Shahad Al-Zubaidi, Abduljaber A'Ed Tayem, Mohammed Ayad Alobi, Anne Sermed Al Sakini, Rami Thair Al-Aish, Khayry Al-Shami, Hamdah Hanifa, Sara S Khunda
{"title":"糖尿病黄斑水肿(DME):剖析发病机制、预后、诊断方法以及当前和未来的治疗见解。","authors":"Ahmed Sermed Al Sakini, Abdulrahman Khaldoon Hamid, Zainab A Alkhuzaie, Sandra Thair Al-Aish, Shahad Al-Zubaidi, Abduljaber A'Ed Tayem, Mohammed Ayad Alobi, Anne Sermed Al Sakini, Rami Thair Al-Aish, Khayry Al-Shami, Hamdah Hanifa, Sara S Khunda","doi":"10.1186/s40942-024-00603-y","DOIUrl":null,"url":null,"abstract":"<p><p>One of the most common health concerns disturbing people within working years globally is diabetes mellitus (DM). One well-known consequence of DM is vascular damage, which can manifest as macro- and microangiopathy affecting the ocular retina. Therefore, Diabetic macular edema (DME) is a major sight-threatening complication of diabetic retinopathy (DR) worldwide. It is the most prevalent cause of significant vision impairment in diabetic patients. Long-term vision loss can be avoided by following early DME treatment guidelines in everyday life. Hence, there are various therapeutic approaches for DME management. Currently, the first-line treatment for DME is anti-VEGF family drugs, such as ranibizumab, brolucizumab, bevacizumab, and aflibercept. Nevertheless, relapses of the disease, inadequate response, and resistance during anti-VEGF therapy are still seen because of the intricate pathophysiological foundation of the disease. Consequently, there is an excellent requirement for therapeutic approaches to advance and become better at controlling diseases more satisfactorily and require fewer treatments overall. We conducted a thorough literature search in the current review to present a comprehensive overview of the primary data about the current DME therapeutic agents. We also covered the novel advances in DME management and probable future treatments being investigated and developed. This review recommended that Large clinical trials should afford sufficient evidence to support these innovative treatment modalities.</p>","PeriodicalId":14289,"journal":{"name":"International Journal of Retina and Vitreous","volume":"10 1","pages":"83"},"PeriodicalIF":1.9000,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11514910/pdf/","citationCount":"0","resultStr":"{\"title\":\"Diabetic macular edema (DME): dissecting pathogenesis, prognostication, diagnostic modalities along with current and futuristic therapeutic insights.\",\"authors\":\"Ahmed Sermed Al Sakini, Abdulrahman Khaldoon Hamid, Zainab A Alkhuzaie, Sandra Thair Al-Aish, Shahad Al-Zubaidi, Abduljaber A'Ed Tayem, Mohammed Ayad Alobi, Anne Sermed Al Sakini, Rami Thair Al-Aish, Khayry Al-Shami, Hamdah Hanifa, Sara S Khunda\",\"doi\":\"10.1186/s40942-024-00603-y\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>One of the most common health concerns disturbing people within working years globally is diabetes mellitus (DM). One well-known consequence of DM is vascular damage, which can manifest as macro- and microangiopathy affecting the ocular retina. Therefore, Diabetic macular edema (DME) is a major sight-threatening complication of diabetic retinopathy (DR) worldwide. It is the most prevalent cause of significant vision impairment in diabetic patients. Long-term vision loss can be avoided by following early DME treatment guidelines in everyday life. Hence, there are various therapeutic approaches for DME management. Currently, the first-line treatment for DME is anti-VEGF family drugs, such as ranibizumab, brolucizumab, bevacizumab, and aflibercept. Nevertheless, relapses of the disease, inadequate response, and resistance during anti-VEGF therapy are still seen because of the intricate pathophysiological foundation of the disease. Consequently, there is an excellent requirement for therapeutic approaches to advance and become better at controlling diseases more satisfactorily and require fewer treatments overall. We conducted a thorough literature search in the current review to present a comprehensive overview of the primary data about the current DME therapeutic agents. We also covered the novel advances in DME management and probable future treatments being investigated and developed. This review recommended that Large clinical trials should afford sufficient evidence to support these innovative treatment modalities.</p>\",\"PeriodicalId\":14289,\"journal\":{\"name\":\"International Journal of Retina and Vitreous\",\"volume\":\"10 1\",\"pages\":\"83\"},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2024-10-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11514910/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Retina and Vitreous\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1186/s40942-024-00603-y\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"OPHTHALMOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Retina and Vitreous","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s40942-024-00603-y","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

糖尿病(DM)是困扰全球工作年龄段人群最常见的健康问题之一。众所周知,糖尿病的后果之一是血管损伤,可表现为影响眼底视网膜的大血管和微血管病变。因此,糖尿病黄斑水肿(DME)是全球糖尿病视网膜病变(DR)中威胁视力的主要并发症。它是糖尿病患者视力严重受损的最主要原因。在日常生活中遵循早期 DME 治疗指南,可以避免长期视力损失。因此,有多种治疗方法可用于 DME 的治疗。目前,抗血管内皮生长因子家族药物(如雷尼珠单抗、布鲁珠单抗、贝伐珠单抗和阿弗利贝赛普)是治疗黑眼圈的一线药物。然而,由于该病的病理生理基础错综复杂,在抗血管内皮生长因子治疗过程中仍会出现疾病复发、反应不足和耐药等情况。因此,治疗方法需要不断进步,以更好地控制疾病,并在整体上减少治疗次数。在本综述中,我们进行了全面的文献检索,对当前二甲双胍治疗药物的主要数据进行了全面概述。此外,我们还介绍了在二极体视网膜病变治疗方面取得的新进展,以及正在研究和开发的未来可能的治疗方法。本综述建议,大型临床试验应提供足够的证据来支持这些创新的治疗方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Diabetic macular edema (DME): dissecting pathogenesis, prognostication, diagnostic modalities along with current and futuristic therapeutic insights.

One of the most common health concerns disturbing people within working years globally is diabetes mellitus (DM). One well-known consequence of DM is vascular damage, which can manifest as macro- and microangiopathy affecting the ocular retina. Therefore, Diabetic macular edema (DME) is a major sight-threatening complication of diabetic retinopathy (DR) worldwide. It is the most prevalent cause of significant vision impairment in diabetic patients. Long-term vision loss can be avoided by following early DME treatment guidelines in everyday life. Hence, there are various therapeutic approaches for DME management. Currently, the first-line treatment for DME is anti-VEGF family drugs, such as ranibizumab, brolucizumab, bevacizumab, and aflibercept. Nevertheless, relapses of the disease, inadequate response, and resistance during anti-VEGF therapy are still seen because of the intricate pathophysiological foundation of the disease. Consequently, there is an excellent requirement for therapeutic approaches to advance and become better at controlling diseases more satisfactorily and require fewer treatments overall. We conducted a thorough literature search in the current review to present a comprehensive overview of the primary data about the current DME therapeutic agents. We also covered the novel advances in DME management and probable future treatments being investigated and developed. This review recommended that Large clinical trials should afford sufficient evidence to support these innovative treatment modalities.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
3.50
自引率
4.30%
发文量
81
审稿时长
19 weeks
期刊介绍: International Journal of Retina and Vitreous focuses on the ophthalmic subspecialty of vitreoretinal disorders. The journal presents original articles on new approaches to diagnosis, outcomes of clinical trials, innovations in pharmacological therapy and surgical techniques, as well as basic science advances that impact clinical practice. Topical areas include, but are not limited to: -Imaging of the retina, choroid and vitreous -Innovations in optical coherence tomography (OCT) -Small-gauge vitrectomy, retinal detachment, chromovitrectomy -Electroretinography (ERG), microperimetry, other functional tests -Intraocular tumors -Retinal pharmacotherapy & drug delivery -Diabetic retinopathy & other vascular diseases -Age-related macular degeneration (AMD) & other macular entities
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信